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Background: The role of hepatic resection for gynaecological tumours is not well defined as evidence
on the subject is lacking. This article describes a tertiary hepatopancreatobiliary unit's experience with
hepatic resection for liver metastases from endometrioid primaries.
Methods: Five women in whom liver metastases developed at 11 months to 10 years post-primary
resection are presented. These patients subsequently underwent hepatic resection with disease-free
survival of 8–66 months post-resection.
Results: Outcomes in this patient series support hepatic resection in the face of isolated liver
metastasis.
Conclusions: The authors advocate that patients with hepatic deposits should be referred to specialist
hepatobiliary units with a view towards hepatic resection and a subsequent good outcome.
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Introduction
The incidence of endometrial cancer is 18.7 cases per 100 000
people in the UK and 5646 patients are newly diagnosed each
year.1 It is estimated that up to 50% of patients who die as a result
of endometrial cancer will demonstrate hepatic metastases at
autopsy.2 Liver resections for metastatic cancer have been reported
for over a century, but it was not until Foster and Berman pub-
lished their landmark report in 1977 that liver resections for meta-
static disease began to achieve general acceptance.3,4 In the setting
of metastatic colorectal cancer, numerous studies have shown
that not only is surgical resection safe, but it also offers the only
potential for cure.2,4 For symptomatic metastatic neuroendocrine
tumours, hepatic resection provides longterm palliation and cure
in a minority of cases.4 Unfortunately, the role of hepatic resection
for gynaecological tumours is less well defined. A plausible reason
for this is that gynaecological carcinomas that metastasize to the
liver tend to do so in the setting of systemic or regional dissemi-
nation, rendering hepatic resection inappropriate. Occasionally,
however, isolated metastasis occurs in which hepatic resection
may be beneficial. This article presents a patient series demon-
strating a tertiary referral hepatopancreatobiliary unit’s experi-
ence of hepatic resection for liver metastases from endometrioid
primaries.
Materials and methods
A database containing details of all patients who underwent liver
resection at the Royal Infirmary of Edinburgh during a 10-year
period from 1 January 2000 to 31 December 2009 was examined
to identify patients who had undergone liver resection for
endometrioid cancer. These patients formed the basis of this
study. The patients were cross-referenced by searching the pathol-
ogy database to ensure that no cases of liver resection for
endometrioid carcinoma had been missed. Pathological confir-
mation of the diagnosis was made in all patients. A selective
literature review was also undertaken using the search terms
‘liver resection’, ‘endometrioid’, ‘ovarian’, ‘endometrial’ and ‘non-
colorectal’ in combination with the Boolean operator ‘AND’.
Results
During the 10-year period of the study (1 January 2000 to 31
December 2009), 617 patients underwent liver resection for a
variety of different causes, of which colorectal cancer was the
most common. Five patients underwent liver resection for
endometrioid cancer during the studyperiod, representing 0.8%of
the total patient group. These patients’ details are presented in
Table 1. Patients 1–4 were given either adjuvant radiotherapy or
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chemotherapy after gynaecological surgery for the primary
tumour. Patient 5 is believed to have developed endometrioid
cancer against a background of endometriosis and did not have a
primary gynaecological malignancy (Figures 1 and 2). No patient
was given planned adjuvant chemotherapy following liver resec-
tion, but patient 4, who developed lung metastases, subsequently
went on to receive palliative chemotherapy as part of a clinical trial.
Discussion
The liver is a common site of metastasis for solid tumours.
Although surgical resection is now considered standard treatment
for resectable metastases from colorectal primaries, the data on
liver resections for gynaecological, particularly endometrial,
carcinoma are sparse.
In this series five women underwent resection of liver deposits
of endometrioid adenocarcinoma. Four patients had metastatic
Table 1 Characteristics of patients undergoing liver resection for endometrioid carcinoma. Age refers to age at liver surgery
Patient
number
Age,
years
Cancer stage Primary operation Adjuvant
treatment
Secondary operation Follow-up,
months
Status
1 59 Endometrial
grade 2,
stage IIIC
TAH + BSO +
lymphadenectomy
Radiotherapy Right trisegmentectomy +
resection of diaphragm
en bloc + prosthetic
reconstruction
48 Alive,
disease-free
2 65 Ovarian grade 3,
stage IC
TAH + BSO +
omentectomy
6 cycles
carboplatin
Segment VI resection +
cholecystectomy
61 Alive,
disease-free
3 59 Endometrial
grade 2,
stage IIIA
TAH + BSO 6 cycles
carboplatin
Right trisegmentectomy
followed by
video-assisted
thoracoscopic left upper
lobectomy as a separate
procedure
66 Alive,
disease-free
4 38 Mixed serous
ovarian
grade 3,
stage IIIc
TAH + BSO +
appendicectomy +
omentectomy +
paraaortic
lymphadenectomy
6 cycles carboplatin
Paclitaxel
Gemcitabine
Right trisegmentectomy +
lymphadenectomy +
excision of nodule
8 Alive,
pulmonary
metastases
5 46 Endometriosis TAH + BSO +
appendicectomy
– Right trisegmentectomy
radical bile duct excision
+ lymphadenectomy
12 Alive,
disease-free
TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy
Table 2 Embryonic derivatives of ovarian adenocarcinoma
Ovarian adenocarcinoma
histological subtype
Mullerian derivative
Serous Fallopian tube
Mucinous Endocervix
Endometrioid (8%) Endometrium
Clear cell Endometrial glands during pregnancy
Figure 1 Macroscopic appearance of endometrioid adenocarcinoma: solid and cystic tumour arising in pre-existing hepatic and perihepatic
endometriosis
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disease from either ovarian or uterine primaries. The fifth patient
is unusual as she is likely to have developed a focus of carcinoma
arising from a hepatic deposit of endometriosis (Table 1). Hepatic
endometriosis is an extremely rare entity of which fewer than 20
cases have been reported in the literature, although malignant
transformation occurs in up to 23% of patients.5,6
The terminology used to describe gynaecological malignancies
can be confusing to clinicians who are not used to dealing with
these diseases. The fallopian tubes, uterus, wall of the vagina and
the surface epithelium of the ovaries share a common embryonic
origin. They develop from mesothelium lining, the gonadal ridge,
which is invaginated to form the Müllerian ducts. When a neo-
plastic process arises in the epithelium of the ovaries, it resembles
a variety of Müllerian-type differentiation, with histological
subtypes representing the shared embryological derivatives of
the ovarian surface epithelium (Table 2.)
Thus ovarian endometrioid adenocarcinoma is thought to
arise from deposits of endometriosis in the ovary; up to 10% of
cases demonstrate a synchronous deposit of endometriosis and
10% show a synchronous endometrial carcinoma with the same
histological features.7 To date, the histological subtype of ovarian
cancer has neither been identified as an independent prognostic
variable nor influenced treatment.8
Endometrial carcinoma has four histological subtypes of which
the endometrioid subtype is the most common, affecting 75–80%
of patients. Unlike in ovarian carcinoma, it is an important
independent variable for prognosis and potential treatment.
Endometrioid endometrial adenocarcinoma has a better progno-
sis than the other subtypes (papillary serous, clear cell or carcino-
sarcoma) and tends to fail locally. These tumours can, however,
metastasize to the lung, bone, brain or liver as solitary deposits
amenable to resection, whereas other histological subtypes tend to
CEA
CA125
ER
CK7
Figure 2 Histology of endometrioid adenocarcinoma arising in pre-existing hepatic and perihepatic endometriosis showing tumour (T) and
surrounding liver (arrows) (upper two panels). Immunohistochemistry shows a classical pattern of staining: both cytokeratin 7 (CK7) and
oestrogen receptor (OR) staining are diffuse; CA125 staining is patchy, and the squamous morules show focal carcinoembryonic antigen
(CEA) staining. CK20 is negative (not shown)
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recur diffusely in the peritoneal cavity and to behave more like
ovarian epithelial malignancies.7
Pathological genetic studies of ovarian cancer suggest a shared
molecular origin for each histological subtype. Each is character-
ized by distinctive, although not unique, molecular defects in
signal pathways that correlate with phenotype and may offer sites
for targeted molecular therapy. Similar genetic abnormalities are
seen in endometrioid adenocarcinoma arising from either the
ovary or the endometrium.8
Liver metastases from ovarian or endometrial cancer at the time
of presentation can represent true haematogenous spread or
peritoneal seeding. Liver capsule metastases in ovarian cancer are
considered to represent stage IIIB or C disease and parenchymal
metastases from either primary to represent stage IV.9 Since the
introduction of platinum-based chemotherapy for gynaecological
malignancies in the 1980s, overall survival in stage IV disease is
less than 20% after optimal cytoreduction.10 Resection of liver
capsule metastases as part of cytoreductive surgery followed by
chemotherapy for ovarian and endometrial malignancy has been
shown to be feasible and may prolong survival.2,11–13 In each of the
first four patients in the current series, liver metastases occurred as
a metachronous event following the completion of radiotherapy
or chemotherapy. Chemosensitivity of the primary tumour may
therefore not be a prerequisite for a successful outcome of liver
resection. What is probably more important is evidence of stable
pelvic disease after resection of the primary tumour. No patients
with synchronous liver metastasis and endometrioid cancer have
been treated or referred for treatment in this centre.
Historical reports have shown no 5-year survivors after
hepatic resection for parenchymal gynaecological metastases.14
Only two reports of hepatic resection in endometrioid
endometrial cancer have been published.2,15 One of these
involved a grade 2 and the other a grade 3 case and
primary surgical treatment was total abdominal hysterectomy
and bilateral salpingo-oophorectomy followed by pelvic radio-
therapy.15 Disease-free survival was 15 months and 70 months,
respectively. Both patients underwent trisegmentectomy fol-
lowed by adjuvant chemotherapy.15 One patient went on to
develop a single brain metastasis 19 months after liver resection,
for which she underwent surgical resection and radiation.2
She went on to survive for 33 months after liver resection.
The other patient unfortunately experienced pulmonary
recurrence 8 months after a combined and bilateral pulmonary
wedge resection and died of disease 2 months after the second
recurrence.15
However, more recent experience reports longterm survival
after resection of hepatic metastases. These cases are published
within retrospective series of liver resections for non-colorectal
non-neuroendocrine (NCNN) liver metastases (Table 3).16–20
Unfortunately, these studies do not report histological subtypes.
Weitz et al. reported on 16 patients, of whom 12 had ovarian and
four had endometrial disease.18 Specific survival times were not
mentioned. The series was grouped with patients with resected
liver metastases from testicular carcinoma and reported to have
the best outcome of liver resection cases for NCNN hepatic
metastases, with 63% of patients disease-free at 3 years and an
actuarial 3-year cancer-specific survival of 78%. The authors also
noted no effect of the disease-free interval on the prognosis, unlike
in the non-reproductive tract liver metastases resected in their
series.17
Table 3 Studies reporting outcomes post-resection of gynaecological hepatic metastases
Study Number of patients in series with
non-colorectal/non-neuroendocrine
liver metastases
Characteristics of
gynaecological
metastases
Outcome(s)
Adam et al. 20061 1452 over 21 years 126 (9%) gynaecological
65 ovarian
43 uterine
18 other (not reported)
Ovarian 50% 5-year overall survival
Uterine 35% 5-year overall survival
Overall 48% 5-year overall survival
In favourable tumour type
O'Rourke et al.17 115 over 20 years
(5% all resections for liver metastases
at centres)
12 of 32 in genitourinary group
12 (12%) all ovarian
Genitourinary group 39%
5-year overall survival
Grouped with renal, bladder, cervix and adrenal
tumours
Weitz et al.18 141 over 21 years
(1001 resections for other metastases
in last 13 years)
19 (14%) of 39 in reproductive
tumours group
12 ovarian
4 endometrial
2 cervical
1 fallopian
20 testicular
Reproductive tumours Actuarial cancer-specific
3-year survival 78%
Yet to reach median survival
Ercolani et al.20 83 over 12.5 years 9 (11%) gynaecological
8 ovarian
1 endometrial
Genitourinary group 5-year survival: 42%
Best outcome with median survival 52 months
Grouped with renal and testicular tumours
Elias et al.19 120 over 12 years
(22% of 538 liver resections over the
same period)
6 (4%) gynaecological Approximately 80% at 3 years
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The series reported by Adam et al.16 and Ercolani et al.20 also
describe favourable survival for primary gynaecological
tumours. The series from Adam et al. describes the largest
number of liver resections for gynaecological metastases. Their
multi-institutional series of 1452 NCNN liver resections
included 126 (9%) cases of either ovarian or uterine primaries,
with an overall 5-year survival of 48%. Five-year survival for
ovarian primaries (50%) exceeded that for endometrial prima-
ries (35%), although no P-value was given.16 Ercolani et al.
grouped eight ovarian and one endometrial patient with liver
metastases with renal and testicular liver metastases patients and
demonstrated the best outcome for tumour type in their series,
with a 5-year survival rate of 42%.
The most recent series reported by O’Rourke et al.17 failed to
find a relationship between tumour type and survival. These
authors published the outcomes of 12 patients with ovarian liver
metastases along with those of 20 other patients with liver
metastases from renal, bladder, cervical and adrenal primaries and
reported a 5-year survival rate of 39%.
These are highly selected series of patients that represent only a
minority of total liver resections for metastases performed in spe-
cialist hepatobiliary units. In each series gynaecological metastases
account for fewer than 10% of cases and are often included for
tumour type uni- or multivariate analysis with testicular, renal or
even bladder and adrenal liver metastases.
It is impossible to determine whether the liver surgery
itself is of benefit. However, common to all series are low
rates of morbidity and mortality and prolonged overall and
disease-free survival rates that seem better than those for his-
torical controls.
In conclusion, recent publications on hepatic resection for
isolated metastases from gynaecological primaries would
support hepatic resection in the face of isolated liver metastases.
Preoperative factors such as fitness for surgery, co-morbidity and
prognostic indicators such as the presence of disseminated
disease and the resectability of hepatic lesions must be taken into
account. To date, no such guidance exists for liver metastases
from gynaecological primaries. However, the criteria used for the
resection of colorectal metastases may be applied: (i) the patient
must be medically fit enough to undergo major abdominal
surgery; (ii) no unresectable extrahepatic tumours demonstrable
on preoperative imaging must be present, and (iii) grossly
negative resection margins leaving an adequate volume
of functional liver must be achievable. This patient series
demonstrates a successful outcome following hepatic resection
for liver metastases from endometrioid primaries, with a
longest disease-free survival of 66 months. The authors advocate
that patients with isolated hepatic deposits and stable
primary disease should be referred to specialist hepatobiliary
units for assessment for hepatic resection. Such treatment should
be considered as part of multimodal therapy and should be
delivered in consultation with specialist gynaecological cancer
specialists.
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